DGAP-News: MOLOGEN AG: Clarification process about the product license was positively concluded as expected - arbitration court claim was rejected
(firmenpresse) - MOLOGEN AG / Key word(s): Legal Matter
02.11.2010 10:06
---------------------------------------------------------------------------
Press release N 14/10 from 11/02/10
MOLOGEN AG - Clarification process about the product license was positively
concluded as expected - arbitration court claim was rejected.
Berlin, November 02, 2010 - As the company disclosed today, the claim
against MOLOGEN AG was rejected and the claimant sentenced to reimburse
costs. Background was the dispute about returning a product license for the
region of India for the cell-based gene therapy against cancer developed by
MOLOGEN AG.
CEO Dr. Matthias Schroff expresses his satisfaction: 'The arbitration court
confirmed with this decision that our assessment of the procedure was
correct from the outset'. (see press release from 19/08/2009)
The issued arbitration decision has the effect of a legally binding court
judgement.
About MOLOGEN AG
Die MOLOGEN AG, a German biopharmaceutical company with headquarters in
Berlin specializes in the research and development of innovative
medications on the basis of DNA structures. The activities focus on
numerous product developments which are relevant to the immune system; on
the one hand vaccines against infectious diseases and on the other hand
cancer medications. MOLOGEN AG is globally one of the few biotechnology
companies with well tolerated DNA-based cancer treatment in the clinical
development phase.
The stocks of MOLOGEN AG are listed in the Prime Standard of the German
stock exchange(ISIN DE0006637200).
Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial
figures,developments of the financial situation or other financial figures
or statistical data, is to be understood as such forward-looking
statements. The company points out to investors that they should not rely
on these forward-looking statements as predictions about actual future
events. The company is not obligated and refuses to accept any liability
for the forward-looking statements and has no obligation to update such
statements in order to accurately reflect the current situation..
Memberships in associations:
BIO Deutschland e.V. | DECHEMA - Society for chemical technology and
biotechnology e.V. | German industrial association of biotechnology (DIB)
| Association for the Promotion of Science and Humanities in Germany |
Association of German biotechnology companies (VBU) | Association of
researching manufacturers of pharmaceuticals e.V. (VFA) | Association of
the chemical industry e.V. (VCI)
MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.
MOLOGEN AG
PRESS SERVICE
Prof. Peter W. Huebner
Director of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Tel: +49 - 30 - 84 17 88 - 50
huebner(at)mologen.com
INVESTOR RELATIONS:
MOLOGEN AG:
Joerg PetraßTel: +49 - 30 - 84 17 88 - 13
Tel: +49 - 30 - 84 17 88 - 50
investor(at)mologen.com
External Investor Relations:
Kirchhoff Consult AG
Dr. Kay Baden
Tel: +49 - 40 - 60 91 86 - 0
Fax: +49 - 40 - 60 91 86 - 16
baden(at)kirchhoff.de
02.11.2010 10:06 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Deutschland
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: info(at)mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Hamburg, München, Düsseldorf, Berlin, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Datum: 02.11.2010 - 10:06 Uhr
Sprache: Deutsch
News-ID 32462
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 168 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: MOLOGEN AG: Clarification process about the product license was positively concluded as expected - arbitration court claim was rejected"
steht unter der journalistisch-redaktionellen Verantwortung von
MOLOGEN AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
